Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

471 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Bariatric surgery for spontaneous ovulation in women living with polycystic ovary syndrome: the BAMBINI multicentre, open-label, randomised controlled trial.
Samarasinghe SNS, Leca B, Alabdulkader S, Dimitriadis GK, Davasgaium A, Thadani P, Parry K, Luli M, O'Donnell K, Johnson B, Abbara A, Seyfried F, Morman R, Ahmed AR, Hakky S, Tsironis C, Purkayastha S, le Roux CW, Franks S, Menon V, Randeva H, Miras AD. Samarasinghe SNS, et al. Among authors: le roux cw. Lancet. 2024 Jun 8;403(10443):2489-2503. doi: 10.1016/S0140-6736(24)00538-5. Epub 2024 May 20. Lancet. 2024. PMID: 38782004 Free article. Clinical Trial.
PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial.
Raal FJ, Stein EA, Dufour R, Turner T, Civeira F, Burgess L, Langslet G, Scott R, Olsson AG, Sullivan D, Hovingh GK, Cariou B, Gouni-Berthold I, Somaratne R, Bridges I, Scott R, Wasserman SM, Gaudet D; RUTHERFORD-2 Investigators. Raal FJ, et al. Lancet. 2015 Jan 24;385(9965):331-40. doi: 10.1016/S0140-6736(14)61399-4. Epub 2014 Oct 1. Lancet. 2015. PMID: 25282519 Clinical Trial.
3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial.
le Roux CW, Astrup A, Fujioka K, Greenway F, Lau DCW, Van Gaal L, Ortiz RV, Wilding JPH, Skjøth TV, Manning LS, Pi-Sunyer X; SCALE Obesity Prediabetes NN8022-1839 Study Group. le Roux CW, et al. Lancet. 2017 Apr 8;389(10077):1399-1409. doi: 10.1016/S0140-6736(17)30069-7. Epub 2017 Feb 23. Lancet. 2017. PMID: 28237263 Free article. Clinical Trial.
Semaglutide and cardiovascular outcomes in patients with obesity and prevalent heart failure: a prespecified analysis of the SELECT trial.
Deanfield J, Verma S, Scirica BM, Kahn SE, Emerson SS, Ryan D, Lingvay I, Colhoun HM, Plutzky J, Kosiborod MN, Hovingh GK, Hardt-Lindberg S, Frenkel O, Weeke PE, Rasmussen S, Goudev A, Lang CC, Urina-Triana M, Pietilä M, Lincoff AM; SELECT Trial Investigators. Deanfield J, et al. Lancet. 2024 Aug 24;404(10454):773-786. doi: 10.1016/S0140-6736(24)01498-3. Lancet. 2024. PMID: 39181597 Free article. Clinical Trial.
Recommendations for the use of LDL apheresis.
Thompson GR; HEART-UK LDL Apheresis Working Group. Thompson GR, et al. Atherosclerosis. 2008 Jun;198(2):247-55. doi: 10.1016/j.atherosclerosis.2008.02.009. Epub 2008 Feb 19. Atherosclerosis. 2008. PMID: 18371971 Review.
Cardiovascular-Liver-Metabolic Health: Recommendations in Screening, Diagnosis, and Management of Metabolic Dysfunction-Associated Steatotic Liver Disease in Cardiovascular Disease via Modified Delphi Approach.
Chew NWS, Mehta A, Goh RSJ, Zhang A, Chen Y, Chong B, Chew HSJ, Shabbir A, Brown A, Dimitriadis GK, Huang DQ, Foo R, le Roux CW, Figtree GA, Fudim M, Pandey A, Mamas MA, Hausenloy DJ, Richards AM, Nicholls SJ, Chan MY, Muthiah MD, Sanyal A, Sperling LS. Chew NWS, et al. Among authors: le roux cw. Circulation. 2025 Jan 7;151(1):98-119. doi: 10.1161/CIRCULATIONAHA.124.070535. Epub 2024 Dec 26. Circulation. 2025. PMID: 39723980 Review.
Data-driven cluster analysis identifies distinct types of metabolic dysfunction-associated steatotic liver disease.
Raverdy V, Tavaglione F, Chatelain E, Lassailly G, De Vincentis A, Vespasiani-Gentilucci U, Qadri SF, Caiazzo R, Verkindt H, Saponaro C, Kerr-Conte J, Baud G, Marciniak C, Chetboun M, Oukhouya-Daoud N, Blanck S, Vandel J, Olsson L, Chakaroun R, Gnemmi V, Leteurtre E, Lefebvre P, Haas JT, Yki-Järvinen H, Francque S, Staels B, Le Roux CW, Tremaroli V, Mathurin P, Marot G, Romeo S, Pattou F. Raverdy V, et al. Among authors: le roux cw. Nat Med. 2024 Dec;30(12):3624-3633. doi: 10.1038/s41591-024-03283-1. Epub 2024 Dec 9. Nat Med. 2024. PMID: 39653777 Free PMC article.
International consensus position statement on the role of obesity management medications in the context of metabolic bariatric surgery: expert guideline by the International Federation for the Surgery of Obesity and Metabolic Disorders (IFSO).
Cohen RV, Busetto L, Levinson R, Le Roux CW, Salminen P, Prager G; International Consensus on the Role of Obesity Management Medications in the Context of Metabolic Bariatric Surgery. Cohen RV, et al. Among authors: le roux cw. Br J Surg. 2024 Nov 27;111(12):znae283. doi: 10.1093/bjs/znae283. Br J Surg. 2024. PMID: 39612579 No abstract available.
Survodutide, a glucagon receptor/glucagon-like peptide-1 receptor dual agonist, improves blood pressure in adults with obesity: A post hoc analysis from a randomized, placebo-controlled, dose-finding, phase 2 trial.
le Roux CW, Steen O, Lucas KJ, Ekinci EI, Startseva E, Unseld A, Hussain SA, Hennige AM. le Roux CW, et al. Diabetes Obes Metab. 2024 Nov 25. doi: 10.1111/dom.16052. Online ahead of print. Diabetes Obes Metab. 2024. PMID: 39582349 No abstract available.
471 results